SWOG clinical trial number
CTSU/E2905

Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid®) Alone and in Combination with Epoetin Alfa (Procrit®) in Subjects with Low- or Intermediate-1 Risk MDS and Symptomatic Anemia

Closed
Abbreviated Title
Phase III Lenalidomide Low-or Intermediate-1 Risk MDS
Activated
02/15/2009
Participants
CTSU

Research committees

Leukemia

Treatment

Allopurinol Fludarabine Phosphate Rituximab

Eligibility Criteria Expand/Collapse

The Southwest Oncology Group has endorsed this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.

Please contact the CTSU directly by phone (888/823-5923) or on the CTSU website (http://www.ctsu.org/) for more information and registration procedures.

Publication Information Expand/Collapse

2021

Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin

A List;Z Sun;A Verma;J Bennett;R Komrokji;K McGraw;L Nardelli;J Maciejewski;J Altman;P Cheema;D Claxton;S Luger;R Mattison;T Wassenaar;A Artz;C Schiffer;M Litzow;M Tallman Journal of Clinical Oncology Mar 20;39(9):1001-1009

PMid: PMID33439748

2019

Combined Treatment with Lenalidomide and Epoetin Alfa leads to Durable Responses in patients with Epo-refractory, Lower Risk Non-deletion 5q [Del(5q)] MDS: Final Results of the E2905 Intergroup Phase III Study - an ECOG-ACRIN Cancer Research Group Study, Grant CA180820, and the National Cancer Institute of the National Institutes of Health

A List;X Sun;A Verma;JM Bennett;K McGraw;L Nardelli;J Maciejewski;J Altman;P Cheema;D Claxton;R Komrokji;S Luger;RJ Mattison;T Wassenaar;A Artz;CA Schiffer;M Tallman Blood (2019) 134 (Supplement_1): 842 (American Society of Hematology (Dec 7-10, 2019, Orlando, FL)), oral, abst. 637